Mass Azithromycin and Malaria Parasitemia in Niger: Results from a Community-Randomized Trial. by O'Brien, Kieran S et al.
UCSF
UC San Francisco Previously Published Works
Title
Mass Azithromycin and Malaria Parasitemia in Niger: Results from a Community-
Randomized Trial.
Permalink
https://escholarship.org/uc/item/17s4c0s7
Journal
The American journal of tropical medicine and hygiene, 97(3)
ISSN
0002-9637
Authors
O'Brien, Kieran S
Cotter, Sun Y
Amza, Abdou
et al.
Publication Date
2017-09-01
DOI
10.4269/ajtmh.16-0487
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Am. J. Trop. Med. Hyg., 97(3), 2017, pp. 696–701
doi:10.4269/ajtmh.16-0487
Copyright © 2017 by The American Society of Tropical Medicine and Hygiene
Mass Azithromycin and Malaria Parasitemia in Niger:
Results from a Community-Randomized Trial
Kieran S. O’Brien,1 Sun Y. Cotter,1 Abdou Amza,2 Boubacar Kadri,2 Baido Nassirou,2 Nicole E. Stoller,1
Zhaoxia Zhou,1 Chris Cotter,3 Sheila K. West,4 Robin L. Bailey,5 Philip J. Rosenthal,6
Bruce D. Gaynor,1,7 Travis C. Porco,1,8 and Thomas M. Lietman1,7,8*
1Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California; 2Programme FSS/Universite´ Abdou
Moumouni de Niamey, Programme National de Sante´ Oculaire, Niamey, Niger; 3Global Health Group, University of California San Francisco,
San Francisco, California; 4Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland;
5Clinical Research Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London,
United Kingdom; 6Department of Medicine, University of California San Francisco, California; 7Department of Ophthalmology,
University of California San Francisco, San Francisco, California; 8Department of Epidemiology and Biostatistics, University of California
San Francisco, San Francisco, California
Abstract. Studies designed to determine the effects of mass administration of azithromycin on trachoma have
suggested that mass azithromycin distributions may also reduce the prevalence of malaria. These studies have
typically examined the impact of a small number of treatments over short durations. In this prespecified substudy of
a cluster-randomized trial for trachoma, we compared malaria parasitemia prevalence in 24 communities in Niger
randomized to receive either annual or biannual mass azithromycin distributions over 3 years. The 12 communities
randomized to annual azithromycin received three treatments during the high-transmission season, and the 12
communities randomized to biannual azithromycin received a total of six treatments: three during the high-
transmission season and three during the low-transmission season. Blood samples were taken to assess malar-
iometric indices among children in all study communities at a single time point during the high-transmission season
after 3 years of the intervention. No significant differences were identified in malaria parasitemia, parasite density,
or hemoglobin concentration between the annual and biannual treatment arms. When compared with annual mass
azithromycin alone, additional mass azithromycin distributions given during the low-transmission season did not
significantly reduce the subsequent prevalence of malaria parasitemia or parasite density after 3 years, as mea-
sured during the high-transmission season.
INTRODUCTION
Azithromycin has been proposed as a potential alternative
or adjunctive option for use in the prevention and treatment
of uncomplicated malaria.1–6 Though azithromycin does
have antimalarial properties, evidence suggests that its
activity against malaria is weak and inferior to first-line
agents as monotherapy, and support for its use in combi-
nation with other antimalarial drugs remains equivocal.7,8
Azithromycin iswell tolerated, however, and is considered to
have minimal risk associated with use in young children and
pregnant women.8–10
Mass distributions of oral azithromycin are currently used to
control ocular strains of Chlamydia in trachoma-endemic
areas. Studies have also identified potential secondary ben-
efits ofmass azithromycin given for trachomaamongchildren,
including reductions in the prevalence of malaria and its
sequelae.11–14 These prior trachoma studies examined the
short-term effects of a small number of mass distributions of
azithromycin on malaria. Trachoma programs typically give
multiple rounds of azithromycin over the course of several
years, however, and the longer term effects of these mass
distributions on malaria are unclear.
A previously published substudy of a large, cluster-
randomized trial for trachoma conducted in Niger found
that malaria parasitemia among children was significantly
lower in communities that received two mass distributions
of azithromycin compared with communities that received
one distribution.11,15 This study suggested that an additional
mass distribution during the low-transmission season con-
tributed to the lower prevalence found after 1 year of treat-
ment.11 Herein, we assess malaria parasitemia among
children in Niger after 3 years of treatment in a different set of
communities randomized to annual or biannual mass distri-
butions of oral azithromycin. This time frame enabled us to
examine longer term effects of multiple distributions of azi-
thromycin on malaria when given during both the low- and
high-transmission seasons.
MATERIALS AND METHODS
Study setting and participants. The Partnership for the
Rapid Elimination of Trachoma was a group of cluster-
randomized trials conducted in The Gambia, Niger, and
Tanzania (clinicaltrials.gov, NCT00792922).15 Eligibility criteria
for study communities have been described in depth pre-
viously.16 Niger communities were eligible for inclusion if the
total population was between 250 and 600 people at the time
of the last government census and the prevalence of active
trachoma among children under 72months of agewas ³ 10%.
In Niger, participants from 48 grappes (smallest government
health unit, termed “community” in this report) in six Centers
de Sante´ Inte´gre´es (CSIs) in the Matameye District of the
Zinder region were included in the trial.
Trial design and randomization. A 2 × 2 factorial design
was used to evaluate both varying treatment frequencies
and targeted treatment coverage levels. Communities were
randomized into four arms with 12 communities each: 1) an-
nual treatment at standard (80%) coverage, 2) annual
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treatment at enhanced (90%) coverage, 3) biannual treatment
at standard (80%) coverage, and 4) biannual treatment at
enhanced (90%) coverage. In this report, the two enhanced
coverage arms comparing annual to biannual treatment at a
target coverageof 90%are examined (2 and4 in thepreceding
list). Within each CSI, stratified blocked randomization of
communities was performed based on clinical trachoma
prevalence in children as described previously.16 An annual
census was conducted before each annual treatment in all
study communities over 3 years. Participants were monitored
for trachoma biannually. Malaria assessments were con-
ducted in 24 communities from the two enhanced coverage
arms after 3 years of treatment.
The statistical package R (version 2.12; R Foundation for
Statistical Computing, Vienna, Austria; www.r-project.org)
was used to generate the random allocation sequence of
clusters (Travis C. Porco).16 Study staff used MS Access
(version 2007; Microsoft Corp., Redmond, WA) to randomly
select individuals for trachoma and malaria assessments.
Intervention. Among the 24 enhanced coverage commu-
nities discussed herein, 12 were randomized to receive an-
nual mass distribution of oral azithromycin in all persons
³ 6months of age, and 12were randomized to receive biannual
mass distribution of oral azithromycin in children 6 months to
12 years of age during the 3-year study period. Annual dis-
tributions were provided during the high-transmission sea-
son for malaria in Niger, and the additional biannual
distributions were provided during the low-transmission
season. In both arms, treatment entailed directly observed
doses of oral azithromycin (20 mg/kg up to a maximum dose
of 1 g in adults).17,18 Children under 6 months of age and
those allergic to macrolides were given topical tetracycline
ointment (1%) to be applied to both eyes twice a day for
6 weeks. In the annual treatment arm, pregnant women were
also offered topical tetracycline. Treatment coverage was
determined based on the census directly preceding
treatment.
Community residents were advised to alert village health
workers within 2 weeks after mass treatment if they and/or
their children experienced an adverse event, defined as di-
arrhea, nausea, and vomiting for more than 2 days, hospital-
ization for any cause, or death. Residents were referred to the
nearest health-care center as needed.
Clinical and laboratory assessments. Blood samples
were collected from children in both the annual and biannual
treatment arms at 36months after study initiation. The study
aimed to collect thick blood smears and hemoglobin con-
centration from 50 children in each study community. Sixty-
two children 6–60months of age from each community were
randomly selected from themost recent census prior to field
data collection. If a community had fewer than 50 children,
blood specimens were taken from all children. After
obtaining verbal consent from a parent or guardian for each
study participant, thick blood smears and hemoglobin
concentration were collected at a centralized exam station
in each community according to methods previously
described.11
Thick blood smears were collected on glass slides, air-
dried, and stored at room temperature. Two experienced
microscopists at the Zinder Regional Hospital in Niger
stained the thick blood smears with 3% Giemsa and used a
light microscope to determine the presence or absence
of Plasmodium parasites on the slides. The microscopists
were masked to treatment arm. If both microscopists ob-
served parasites, then the smear was considered positive.
Discordant slides were considered negative. To assess
parasite density, the microscopists counted the number of
asexual parasites per 200 white blood cells (assuming white
blood cell count = 8,000/μL).19 The average of the two par-
asite density readings was used in analyses. Gametocytes
were considered present if observed by either microscopist,
given the low prevalence. Hemoglobin concentration was
determined for all randomly selected children (HemoCue AB,
A¨ngelholm, Sweden).
Sample size and statistical analysis. We estimated that
24 communities (12 communities per arm) would provide
greater than 80%power to detect a 3% absolute difference in
malaria parasitemia. The sample size calculation assumed a
baseline prevalence of 10% and an intraclass correlation co-
efficient (ICC) of 0.075.20
The primary analysis accounted for clustering at the level
of the randomization unit (community) by comparing the
community prevalence of malaria parasitemia in the annual
and biannual treatments at 36 months after study initiation
arms using a paired t test. To ensure results were not de-
pendent on assumptions, sensitivity analyses were con-
ducted with nonparametric tests (Wilcoxon signed rank) at
the community level. A mixed-effects logistic regression
model was used to examine effects at the individual level
while clustering for community. Secondary outcomes, par-
asite density, gametocytemia, and hemoglobin concentra-
tion, were assessed similarly. All analyseswere performed as
intent-to-treat using Stata 13 (Statacorp LP, College Sta-
tion, TX).
Ethics statement. Ethical approval was obtained from the
University of California, San Francisco Committee for Hu-
man Research and the Comite´ d’Ethique du Niger (the Eth-
ical Committee of Niger). This study is registered at
clinicaltrials.gov (NCT00792922) and was implemented in
accordance with the Declaration of Helsinki. Given the high
rates of illiteracy in the study area, the institutional review
boards approved verbal informed consent, both from the
local chiefs of each community before randomization and
each child participant’s parent or guardian before data
collection.
RESULTS
Participants and treatment coverage. From May 2010 to
September 2013, 24 communities in the enhanced (90%)
coverage arm of the main Niger trial were followed. At base-
line, the 12 communities randomized to annual mass azi-
thromycin had amean of 138 children (range, 75–222) and the
12 biannually treated communities had amean of 125 children
(range, 61–267) 6–60 months of age (Figure 1). As shown in
Table 1, baseline characteristics of eligible children were
comparable between treatment arms.
All communities received threemass antibiotic distributions
during the high-transmission season (June/July 2010,
June/July 2011, and June/July 2012). The 12 communities
randomized to biannual mass azithromycin were treated an
additional three times during the low-transmission season
(December 2010/January 2011, December 2011/January
2012, and December 2012/January 2013). Treatment
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coverage is shown in Table 2. Themean antibiotic coverage
of children 6–60 months of age was greater than 90%
across all treatment periods in both arms. All study com-
munities were treated per protocol and no communities
were lost to follow-up. No serious adverse events were
reported during the study period.
Assessments of malaria parasitemia and hemoglobin
levels. Children from each study community were randomly
FIGURE 1. Participant flow in the Partnership for the Rapid Elimination of Trachoma cluster-randomized trial in Niger.
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selected for this substudy from the most recent census in May
2013. Thick blood smears were collected from a total of 1,032
children in 24 communities (485 in the annual treatment arm;
547 in the biannual treatment arm) 3 years after enrollment
(September 2013, high-transmission season). Hemoglobin
concentration was collected from 1,033 children (486 in the
annual treatment arm; 547 in the biannual treatment arm).
Specimen collection occurred more than 1 year after the last
treatment in the annually treated communities and approxi-
mately8monthsafter the last treatment in thebiannually treated
communities.
Grades for the presence or absence of malaria parasites were
concordant between the twomicroscopists in 99.4%of samples
withan ICCof0.994 (95%confidence interval [CI]=0.993–0.995).
Comparing the two assessments of parasite density resulted in
an ICC of 0.957 (95% CI = 0.951–0.962). Table 3 shows the
results for all assessments.At thesingle timepoint after 3yearsof
mass azithromycin distribution, the community-level prevalence
of parasitemia was similar in the biannually treated communities
and the annually treated communities (mean difference = 0.00,
95% CI = _0.15 to 0.15, P = 0.995). A mixed-effects logistic
regression model with treatment arm as a fixed effect and
community as a random effect showed similar results (odds
ratio = 1.00, 95% CI = 0.58–1.73, P = 0.997). No significant
differences were seen in community-level parasite density,
gametocytemia, or hemoglobin concentration when com-
paring annually treated communities to biannually treated
communities. Analyses conducted with Wilcoxon signed
rank tests and mixed-effects regression models for each of
these three assessments showed similar results.
DISCUSSION
In this cluster-randomized trial, we were unable to demon-
strate a difference in malaria parasitemia, parasite density, or
hemoglobin concentration between children who received
annual or biannual treatment with azithromycin after 3 years of
the intervention. A previous study in Niger found a significant
reduction in malaria parasitemia and parasite density in
communities with an additional treatment during the low-
transmission season compared with communities with a sin-
gle mass treatment after 1 year.11 In this study, we assessed
the effect of mass distributions of azithromycin onmalaria in a
different set of communities over a longer time period during
the high-transmission season.
There are several possible explanations for the discrep-
ancy in results between annual and biannual azithromycin
after 1 year compared with 3 years. Azithromycin may lose
TABLE 1
Baseline characteristics of children £ 30 months at time of enrollment
in 24 communities randomized to annual or biannual mass
azithromycin in a cluster-randomized trial in Niger
Characteristic
Mean (95% confidence interval or range)
Annual azithromycin
N = 12 communities
Biannual azithromycin
N = 12 communities
Children per community 72 (range, 37–119) 66 (range, 36–124)
Proportion female (%) 52.1% (49.3–54.8) 49.0% (45.1–52.9)
Age (months) 18.4 (17.3–19.4) 18.7 (17.4–19.9)
Prevalence of TF* 23.4% (14.9–32.0) 17.6% (12.5–22.7)
Prevalence of TI* 7.1% (1.0–13.3) 5.0% (1.9–8.2)
* Trachomatous inflammation—follicular (TF) and trachomatous inflammation—intense (TI)
assessed according to the World Health Organization Simplified Grading System.
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effectiveness after multiple mass treatments due to in-
creasing resistance. A previous study suggested that
azithromcyin–artesunate treatment failuremay have resulted
from Plasmodium species resistance after mass azi-
thromycin for trachoma in the area.21 Another study, how-
ever, failed to identify markers of resistance to azithromycin
on a gene suspected to be involved in azithromycin re-
sistance in vitro, though this study examined resistance after
a single mass treatment.13 In general, little is known about
parasite resistance to macrolides.
Another explanation for the difference in study results
could be that the previous study assessed malaria out-
comes in the low-transmission season and the present
study assessed outcomes in the high-transmission season.
Single mass treatments with azithromycin have shown re-
ductions inmalaria prevalence immediately after treatment,
but these reductions are not maintained over time without
additional treatment.14 An effect of azithromycin might be
expected during the low-transmission season when re-
infection is uncommon, but the lack of an effect during the
high-transmission season may be due to the high malaria
risk that remains even after azithromycin’s protective ef-
fects decline. Alternatively, the significant reduction in
malaria parasitemia seen in the biannual treatment arm after
1 year may have been due to chance.
This study has several important limitations. First, no
baseline assessment of the prevalence of malarial para-
sitemia was conducted, which may have revealed whether
parasitemia decreased in both arms. Baseline prevalence
could have offered a more powerful study design, though
randomized posttest analysis does permit valid inference,22
since treatment assignments are stochastically independent
of other explanatory covariates.23 In addition, the treatment
schedule and dosage for the study was designed for tra-
choma control, not malaria prevention. Seasonal malaria
chemoprevention has demonstrated efficacy when admin-
istered during the high-transmission season in areas like
Niger with seasonal malaria.24,25 However, a mathematical
model of malaria transmission dynamics in Niger demon-
strated that mass azithromycin distributions during the high-
transmission season may not necessarily be the most
effective in reducing malaria transmission.26 Our previous
study also provides some evidence that an intervention with
azithromycin during the low-transmission season may be
beneficial.11 It may be the case that single mass treatments
during the low-transmission season provide protection, but
repeated treatmentswould be required to reducemalaria risk
during the high-transmission season. This study also did not
include confirmatory antibiotic resistance testing, so it was
not possible to examine the potential relationship between
antibiotic resistance after 3 years of mass treatment and
malaria parasitemia. Finally, this study only compared the
effects of mass azithromycin on children receiving either
annual or biannual treatment. A comparison of the effects of
multiple rounds of mass azithromycin to no treatment could
provide a more complete examination of the impact of mass
azithromycin.
After 3 years of multiple distributions of mass azi-
thromycin, wewere unable to show a significant reduction in
community-level prevalence of malaria parasitemia during
the high-transmission season in communities randomized
to biannual versus annual treatment. In this setting, addi-
tional mass azithromycin distributions during the low-
transmission seasons did not reduce community-level
prevalence of malaria parasitemia or parasite density.
Mass azithromycin may have a modest impact on malaria
prevalence during the low-transmission season, but there
may be little protection from reinfection after a single treat-
ment during the high-transmission season. Additional
studies could examine malaria risk over time to better
compare the impacts of different azithromycin distributions
on malaria prevalence during both the low- and high-
transmission seasons.
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